Nigel H. Greig

32.1k total citations · 9 hit papers
431 papers, 25.6k citations indexed

About

Nigel H. Greig is a scholar working on Molecular Biology, Pharmacology and Physiology. According to data from OpenAlex, Nigel H. Greig has authored 431 papers receiving a total of 25.6k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Molecular Biology, 137 papers in Pharmacology and 119 papers in Physiology. Recurrent topics in Nigel H. Greig's work include Cholinesterase and Neurodegenerative Diseases (127 papers), Alzheimer's disease research and treatments (99 papers) and Computational Drug Discovery Methods (58 papers). Nigel H. Greig is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (127 papers), Alzheimer's disease research and treatments (99 papers) and Computational Drug Discovery Methods (58 papers). Nigel H. Greig collaborates with scholars based in United States, Taiwan and Saudi Arabia. Nigel H. Greig's co-authors include Debomoy K. Lahiri, David Tweedie, Kumar Sambamurti, Harold W. Holloway, Mark P. Mattson, Yazhou Li, TracyAnn Perry, Mohammad Amjad Kamal, Qian‐sheng Yu and Josephine M. Egan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Nigel H. Greig

421 papers receiving 25.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

2019 1.3k citations Nigel H. Greig, Mark P. Mattson et al. profile →
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms

2017 649 citations Nigel H. Greig, Mark P. Mattson et al. profile →
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

2005 645 citations Nigel H. Greig, Harold W. Holloway et al. Proceedings of the National Academy of Sciences profile →
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

2017 603 citations Yazhou Li, Nigel H. Greig et al. profile →
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

2009 502 citations Yazhou Li, Mark S. Kindy et al. Proceedings of the National Academy of Sciences profile →
Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function

2016 417 citations Nigel H. Greig et al. profile →
Drug discovery and development: Role of basic biological research

2017 377 citations Nigel H. Greig et al. profile →
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

2022 152 citations Elliot J. Glotfelty, Yazhou Li et al. profile →
The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

2023 72 citations Nigel H. Greig, Yazhou Li et al. profile →

Peers

Countries citing papers authored by Nigel H. Greig

Since Specialization

Citations

This map shows the geographic impact of Nigel H. Greig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel H. Greig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel H. Greig more than expected).

Fields of papers citing papers by Nigel H. Greig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel H. Greig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel H. Greig. The network helps show where Nigel H. Greig may publish in the future.

Co-authorship network of co-authors of Nigel H. Greig

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel H. Greig. A scholar is included among the top collaborators of Nigel H. Greig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel H. Greig. Nigel H. Greig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Balancing hope and heart: An umbrella review of cardiotoxicity in immune checkpoint inhibitor cancer therapies 2025 ·Current Problems in Cardiology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sneha Annie Sebastian, (unknown), Gurpreet Johal, Nigel H. Greig	0
2	Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities 2025 ·Biochemical and Biophysical Research Communications ·Weiming Luo, (unknown), David Tweedie, Cindy H. Chau, Chirag Patel, Maxime A. Siegler, Neil Vargesson, Inho Hwang, Soyeon Kim, (unknown), William D. Figg, Nigel H. Greig	0
3	3-Monothiopomalidomide, a new immunomodulatory imide drug (IMiD), blunts inflammation and mitigates ischemic stroke in the rat 2025 ·GeroScience ·Kai‐Yun Chen, Shih‐Chang Hsueh, (unknown), (unknown), David Tweedie, Weiming Luo, Chirag J. Patel, Yung‐Hsiao Chiang, Nicholas C. Bambakidis, Barry J. Hoffer, (unknown), (unknown), (unknown), Yun Wang, Eunji Hong, Dong Seok Kim, Nigel H. Greig	1
4	Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration 2024 ·Biomolecules ·(unknown), Yazhou Li, Elliot J. Glotfelty, David Tweedie, Nigel H. Greig	9
5	A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders 2023 ·Biomolecules ·(unknown), (unknown), Elliot J. Glotfelty, Shih‐Chang Hsueh, David Tweedie, (unknown), Marcella Reale, Neil Vargesson, Nigel H. Greig	13
6	Microglial Nogo delays recovery following traumatic brain injury in mice 2023 ·Glia ·Elliot J. Glotfelty, Shih‐Chang Hsueh, (unknown), (unknown), (unknown), (unknown), Binhai Zheng, Yu Luo, Tobias E. Karlsson, Ross A. McDevitt, (unknown), Nigel H. Greig	4
7	Mitigating chronic neuroinflammation in Alzheimer mice by novel immunomodulatory imide drugs (IMiDs) conserves neuroplasticity and cognitive function and also alleviates neurodegeneration‐behavioral impairments in TBI‐challenged mice 2023 ·Alzheimer s & Dementia ·Nigel H. Greig, Daniela Lecca, Shih‐Chang Hsueh, David Tweedie, Michael T. Scerba, Barry J. Hoffer, Jia‐Yi Wang, Kumar Sambamurti, Debomoy K. Lahiri, Dong Seok Kim	1
8	Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID 2022 ·ACS Chemical Neuroscience ·Abdul Mannan Baig, Nigel H. Greig, (unknown), (unknown), (unknown), (unknown), Tazeen Saeed Ali	2
9	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer’s Disease 2021 ·Cells ·Francheska Delgado‐Peraza, Carlos Nogueras‐Ortiz, Olga V. Volpert, Dong Liu, Edward J. Goetzl, Mark P. Mattson, Nigel H. Greig, (unknown), Dimitrios Kapogiannis	55
10	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs 2020 ·Molecules ·Megan L. Peach, Shaunna Beedie, Cindy H. Chau, (unknown), (unknown), Weiming Luo, David Tweedie, Christian Steinebach, Nigel H. Greig, Michael Gütschow, Neil Vargesson, Marc C. Nicklaus, William D. Figg	14
11	Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6′-Dithiothalidomide on Traumatic Brain Injury 2019 ·International Journal of Molecular Sciences ·(unknown), (unknown), Michael T. Scerba, David Tweedie, Nigel H. Greig, Jonathan P. Miller, Barry J. Hoffer, (unknown), Jia‐Yi Wang	27
12	Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon 2019 ·Scientific Reports ·Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Ho Jung, Hee Kyung Kim, Hoil Choi, Dong Seok Kim, Julie A. Mattison, Nigel H. Greig	18
13	Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury 2018 ·Neurobiology of Disease ·(unknown), Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot J. Glotfelty, Lital Rachmany, (unknown), Hoil Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig, Dong Seok Kim	27
14	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities 2018 ·Bioorganic & Medicinal Chemistry ·Weiming Luo, David Tweedie, Shaunna Beedie, Neil Vargesson, William D. Figg, Nigel H. Greig, Michael T. Scerba	16
15	Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond 2014 ·IUScholarWorks (Indiana University) ·Nigel H. Greig, Debomoy K. Lahiri	1
16	Incretin mimetics as pharmacological tools to elucidate and as a new drug strategy to treat traumatic brain injury 2014 ·PMC ·Nigel H. Greig, David Tweedie, Lital Rachmany, Yazhou Li, Vardit Rubovitch, Shaul Schreiber, Yung‐Hsiao Chiang, Barry J. Hoffer, Jonathan P. Miller, Debomoy K. Lahiri, Kumar Sambamurti, Robert E. Becker, Chaim G. Pick	25
17	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism breakdown → 2009 ·Proceedings of the National Academy of Sciences ·Yazhou Li, (unknown), Mark S. Kindy, Brandon K. Harvey, David Tweedie, Harold W. Holloway, Kathleen Powers, Hui Shen, Josephine M. Egan, Kumar Sambamurti, Arnold Brossi, Debomoy K. Lahiri, Mark P. Mattson, Barry J. Hoffer, Yun Wang, Nigel H. Greig	502
18	A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis 2006 ·Current Alzheimer Research ·Kumar Sambamurti, Anitha Suram, Chitra Venugopal, A. Prakasam, Yan Zhou, Debomoy K. Lahiri, Nigel H. Greig	49
19	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats 2000 ·Endocrinology ·(unknown), Maı̀re E. Doyle, (unknown), Harold W. Holloway, Richard G. Spencer, Nigel H. Greig, Josephine M. Egan	253
20	Cerebrovascular Biology and the Various Neural Barriers: Challenges and Future Directions 1999 ·Neurosurgery ·Edward A. Neuwelt, N. Joan Abbott, Lester R. Drewes, Quentin R. Smith, Pierre Olivier Couraud, E. Antonio Chiocca, Kenneth L. Audus, Nigel H. Greig, Nancy D. Doolittle	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact